Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
Holding UTHR?
Track your performance easily
See the Price Targets and Ratings of:
UTHR Analyst Ratings
Moderate Buy
8 Buy
2 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
UTHR Stock 12 Month Forecast
Average Price Target
$325.55
▼(-0.52% Downside)
| Highest Price Target$400.00 | Average Price Target$325.55 | Lowest Price Target$240.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Morgan Stanley
Downgraded
07/11/24
TD Cowen
Assigned
07/11/24
Argus Research
Reiterated
07/08/24
Oppenheimer
Reiterated
06/27/24
Bank of America Securities
Reiterated
06/26/24
Wells Fargo
Assigned
06/12/24
J.P. Morgan
Reiterated
05/21/24
H.C. Wainwright
Reiterated
05/02/24
Goldman Sachs
Reiterated
05/02/24
Leerink Partners
$335→$338
Buy
3.28%
Upside
Reiterated
05/01/24
We're not surprised that UTHR stock closed up ~9% (vs -0.33% for NASDAQ), as we believe investors were encouraged by the rev beat and by mgmt. voicing that they are starting to see a “bend upwards” in Tyvaso’s uptake trajectory that should continue in the quarters ahead as more rev drivers kick in. With the expanded Tyvaso salesforce fully deployed as of Jan 1, mgmt expects to see the positive impact on the Tyvaso business starting 3Q24, which could further accelerate Tyvaso’s momentum. Going forward, we think investors will have the following questions: a) how long can UTHR sustain this inflection? and b) how much growth acceleration should we expect through YE24? Key takeaways from the call include: (1) 1Q24 revs of ~$373M (~6% increase Q/Q, ~56% increase Y/Y) were 3%/1% above our/ consensus est.
Ladenburg Thalmann & Co.
$264→$262
Buy
-19.94%
Downside
Reiterated
02/22/24
United Therapeutics price target lowered to $262 from $264 at LadenburgUnited Therapeutics price target lowered to $262 from $264 at Ladenburg
BTIG
―
Hold
―
Assigned
02/21/24
United Therapeutics: A Balanced Hold Amid Growth and Market Challenges
Jefferies
$315
Buy
-3.75%
Downside
Reiterated
01/10/24
Wall Street Analysts Are Bullish on Top Healthcare Picks
Best Analysts Covering United Therapeutics
Which Analyst Should I Follow If I Want to Buy UTHR and Sell After:
1 Month
xxx
Success Rate
10/14 ratings generated profit
Average Return
+3.19%
reiterated a xxx
rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +3.19% per trade.
3 Months
xxx
Success Rate
9/11 ratings generated profit
Average Return
+15.33%
assigned a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 81.82% of your transactions generating a profit, with an average return of +15.33% per trade.
1 Year
2 Years
xxx
Success Rate
18/18 ratings generated profit
Average Return
+47.66%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +47.66% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
UTHR Analyst Recommendation Trends
Rating
Mar 24
Apr 24
May 24
Jun 24
Jul 24
Strong Buy
2
3
3
3
2
Buy
11
12
12
9
10
Hold
2
2
1
1
2
Sell
0
0
0
1
1
Strong Sell
0
0
0
0
0
total
15
17
16
14
15
Each month's total comprises the sum of three months' worth of ratings.
UTHR Financial Forecast
UTHR Stock Forecast FAQ
What is UTHR’s average 12-month price target, according to analysts?
Based on analyst ratings, United Therapeutics’s 12-month average price target is $325.55.
What is UTHR’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for UTHR, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is UTHR a Buy, Sell or Hold?
United Therapeutics has a consensus rating of Moderate Buy which is based on 8 buy ratings, 2 hold ratings and 1 sell ratings.
What is United Therapeutics’s price target?
The average price target for United Therapeutics is $325.55. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $400.00 ,the lowest forecast is $240.00. The average price target represents -0.52% Decrease from the current price of $327.26.
The highest analyst price target is $400.00 ,the lowest forecast is $240.00. The average price target represents -0.52% Decrease from the current price of $327.26.
What do analysts say about United Therapeutics?
United Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of UTHR?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.